ENDRA Life Sciences Inc.
NDRA· Nasdaq
NDRAENDRA Life Sciences Inc.
Filed Mar 16, 2023 · 10-K · 75 days after period end · 0001654954-23-003044
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures |
|---|---|---|---|---|
| Revenue | — | — | — | $0.00 |
| Net Income | -$3.29M | -$3.10M | -$2.25M | -$4.81M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ENDRA Life Sciences Inc. · CIK 1681682 · Engraved from SEC EDGAR
ended Dec 31, 2022 · filed Mar 16, 2023 · 75 d after period end
